Assessing the Genomic Landscape of Cervical Cancers: Clinical Opportunities and Therapeutic Targets
Claire F Friedman,Vignesh Ravichandran,Kathryn Miller,Chad Vanderbilt,Qin Zhou,Alexia Iasonos,Malavika Vivek,Pamela Mishra,Mario M Leitao Jr,Vance Broach,Yukio Sonoda,Chrisann Kyi,Dmitriy Zamarin,Roisin E O'Cearbhaill,Jason Konner,Michael F Berger,Britta Weigelt,Amir Momeni Boroujeni,Kay J Park,Carol Aghajanian,David B Solit,Mark T A Donoghue
DOI: https://doi.org/10.1158/1078-0432.CCR-23-1078
2023-11-14
Abstract:Purpose: Tumor genomic profiling is increasingly used to guide treatment strategy in patients with cancer. We integrated tumor genomic, clinical demographic, and treatment response data to assess how prospective tumor-normal sequencing impacted treatment selection in patients with cervical cancer. Experimental design: Cervical cancers were prospectively analyzed using the MSK-IMPACT (Memorial Sloan Kettering Cancer Center - Integrated Mutation Profiling of Actionable Cancer Targets) next-generation sequencing panel. Clinical data, including histology, stage at diagnosis, treatment history, clinical trial enrollment and outcomes, date of last follow-up, and survival status were obtained from medical records. Results: A total of 177 patients with cervical cancer (squamous, 69; endocervical adenocarcinoma, 50; gastric type, 22; adenosquamous, 21; and other, 15) underwent MSK-IMPACT testing. The most prevalent genomic alterations were somatic mutations or amplifications in PIK3CA (25%), ERBB2 (12%), KMT2C (10%), and KMT2D (9%). Furthermore, 13% of patients had high tumor mutational burden (TMB >10 mut/Mb), 3 of which were also microsatellite instability-high (MSI-H). Thirty-seven percent of cases had at least one potentially actionable alteration designated as a level 3B mutational event according to the FDA-recognized OncoKB tumor mutation database and treatment classification system. A total of 30 patients (17%) were enrolled on a therapeutic clinical trial, including 18 (10%) who were matched with a study based on their MSK-IMPACT results. Twenty patients (11%) participated in an immune checkpoint inhibition study for metastatic disease; 2 remain progression free at >5 years follow-up. Conclusions: Tumor genomic profiling can facilitate the selection of targeted/immunotherapies, as well as clinical trial enrollment, for patients with cervical cancer.